

Long-Chain Arylpiperazine Derivatives with Cyclic Amino Acid Amide Fragments as Potential 5-HT₇ Receptor Ligands.

Paweł Guzik¹, Vittorio Canale¹, Pascal Verdie², Rafał Kurczab³,
Grzegorz Satała³, Maciej Pawłowski¹, Jean Martinez²,
Gilles Subra², Andrzej J. Bojarski³, Paweł Zajdel¹

¹ Department of Medicinal Chemistry, Faculty of Pharmacy,
Jagiellonian University Medical College, Medyczna 9, Kraków, Poland


² Department of Amino Acids, Peptides and Proteins, Institute Biomolecules Max Mousseron,
UMR 5247, CNRS, University Montpellier I, 15 Charles Flahault, 34-093 Montpellier, France

³ Department of Medicinal Chemistry, Institute of Pharmacology,
Polish Academy of Sciences, Smętna 12, Kraków, Poland

e-mail: mfzajdel@cyf-kr.edu.pl

Recently, the 5-HT₇ receptor (5-HT₇R) has emerged as a new target with a potential for the treatment of psychiatric disorders. It was evidenced that the antidepressant-like effects of well-known atypical antipsychotics amisulpride and aripiprazole are mediated by 5-HT₇R antagonism [1]. More recently, it was shown that the 5-HT₇R may significantly influence cognitive dysfunction and therefore represent a potential therapeutic target for the treatment of memory dysfunction in cognitive disorders (Alzheimer's disease, age-related decline) [2].

As a part of our efforts in identifying selective 5-HT₇ receptor ligands with arylpiperazine structure we designed a series of LCAPs containing amino acid amide fragments (pyrrolidine-2-carboxamide, 1,2,3,4-tetrahydroisoquinoline-3-carboxamide). Herein we present our initial data on design, solid-phase synthesis and biological evaluation of a 48 member library.



Selected library representatives displayed high-to low affinity for 5-HT_{1A} ($K_i = 0.2$ –6307 nM), 5-HT₇ ($K_i = 18$ –3134 nM), and D₂ ($K_i = 25$ –2892 nM) receptors. Herein, we examine an influence of position and character of a series of electronic and polar substituents and discuss on structural features determining 5-HT_{1A} and 5-HT₇ receptor affinity and selectivity.

[1] Leopoldo M., *et al.*: *Pharmacol. Ther.* **129** (2011), 120-148.

[2] Matthys A., *et al.*: *Mol. Neurobiol.* **43** (2011), 228–253.

This study was partly supported by the Polish Ministry of Science and Higher Education (MNiSW), Grant No. N N405 671540.